Pipeline

Levels Dx currently has three projects under development. The first project focuses on early diagnosis of the most common type of liver cancer: hepatocellular carcinoma (HCC). Together with the Leiden University Medical Center (LUMC), Levels Dx identified a combination of biomarkers that can detect early-stage HCC with more accuracy than the current clinical standard. To further validate these biomarkers, the company is working on the organization of new clinical trials with larger patient cohorts.